Interleukin 6 and rheumatoid arthritis

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Yoshida, Yuji ^a   Tanaka, Toshio ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; INTERLEUKIN 6;

ANIMAL; BIOLOGICAL MODEL; CELL LINE; HUMAN; MOUSE; REVIEW; RHEUMATOID ARTHRITIS; TRANSGENIC MOUSE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL LINE; HUMANS; INTERLEUKIN-6; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL;

EID: 84893733932     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/698313     Document Type: Review

References (100)

1. McInnes I. B., Schett G., The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine 2011 365 23 2205 2219 2-s2.0-84855172814
2. Smolen J. S., Aletaha D., Bijlsma J. W., Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases 2010 69 4 631 637 10.1136/ard.2009.123919
3. Tanaka T., Ogata A., Narazaki M., Tocilizumab for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 2010 6 6 843 854 2-s2.0-78049445876 10.1586/eci.10.70
4. Tanaka T., Narazaki M., Kishimoto T., Therapeutic targeting of the interleukin-6 receptor. Annual Review of Pharmacology and Toxicology 2012 52 199 219 2-s2.0-84555200149 10.1146/annurev-pharmtox-010611-134715
5. Tanaka T., Ogata A., Kishimoto T., Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update. Rheumatology: Current Research 2013 3 2, article S4:002
6. Yoshizaki K., Nakagawa T., Kaieda T., Muraguchi A., Yamamura Y., Kishimoto T., Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. The Journal of Immunology 1982 128 3 1296 1301 2-s2.0-0020081571 (Pubitemid 12188454)
7. Kishimoto T., Factors affecting B-cell growth and differentiation. Annual Review of Immunology 1985 3 133 157 2-s2.0-0022315832
8. Hirano T., Yasukawa K., Harada H., Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986 324 6092 73 76 2-s2.0-0022499547 (Pubitemid 16008419)
9. Suematsu S., Matsusaka T., Matsuda T., Ohno S., Miyazaki J.-I., Yamamura K. I., Hirano T., Kishimoto T., Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1992 89 1 232 235 2-s2.0-0026604568
10. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H., Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proceedings of the National Academy of Sciences of the United States of America 1987 84 20 7251 7255 2-s2.0-0023432812
11. Heinrich P. C., Castell J. V., Andus T., Interleukin-6 and the acute phase response. Biochemical Journal 1990 265 3 621 636 2-s2.0-0025190892 (Pubitemid 20053863)
12. Hirano T., Akira S., Taga T., Kishimoto T., Biological and clinical aspects of interleukin 6. Immunology Today 1990 11 12 443 449 2-s2.0-0025226107
13. Akira S., Taga T., Kishimoto T., Interleukin-6 in biology and medicine. Advances in Immunology 1993 54 1 78 2-s2.0-0027421831 (Pubitemid 23289250)
14. Kishimoto T., Interleukin-6: from basic science to medicine-40 years in immunology. Annual Review of Immunology 2005 23 1 21 2-s2.0-17644368573 10.1146/annurev.immunol.23.021704.115806 (Pubitemid 40563163)
15. Yamasaki K., Taga T., Hirata Y., Yawata H., Kawanishi Y., Seed B., Taniguchi T., Hirano T., Kishimoto T., Cloning and expression of the human interleukin-6 (BSF-2/IFN β 2) receptor. Science 1988 241 4867 825 828 2-s2.0-0023685762
16. Kishimoto T., Akira S., Taga T., Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992 258 5082 593 597 2-s2.0-0026485304
17. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T., Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989 58 3 573 581 2-s2.0-0024393839 (Pubitemid 19203542)
18. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T., Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990 63 6 1149 1157 2-s2.0-0025630163 10.1016/0092-8674(90)90411-7 (Pubitemid 120035064)
19. Lutticken C., Wegenka U. M., Yuan J., Buschmann J., Schindler C., Ziemiecki A., Harpur A. G., Wilks A. F., Yasukawa K., Taga T., Kishimoto T., Barbieri G., Pellegrini S., Sendtner M., Heinrich P. C., Horn F., Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994 263 5143 89 92 2-s2.0-0028296179 (Pubitemid 24076262)
20. Stahl N., Boulton T. G., Farruggella T., Ip N. Y., Davis S., Witthuhn B. A., Quelle F. W., Silvennoinen O., Barbieri G., Pellegrini S., Ihle J. N., Yancopoulos G. D., Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components. Science 1994 263 5143 92 95 2-s2.0-0028281794 (Pubitemid 24076263)
21. Rose-John S., IL-6 trans-signaling via the soluble IL-6 receptor: importance for the proinflammatory activities of IL-6. International Journal of Biological Sciences 2012 8 9 1237 1247
22. Akira S., Nishio Y., Inoue M., Wang X.-J., Wei S., Matsusaka T., Yoshida K., Sudo T., Naruto M., Kishimoto T., Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994 77 1 63 71 2-s2.0-0028303977
23. Stahl N., Farruggella T. J., Boulton T. G., Zhong Z., Darnell J. E. Jr., Yancopoulos G. D., Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995 267 5202 1349 1353 2-s2.0-0028931604
24. Gerhartz C., Heesel B., Sasse J., Hemmann U., Landgraf C., Schneider-Mergener J., Horn F., Heinrich P. C., Graeve L., Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130: I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. The Journal of Biological Chemistry 1996 271 22 12991 12998 2-s2.0-0029887373
25. Kuropatwinski K. K., de Imus C., Gearing D., Baumann H., Mosley B., Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6. The Journal of Biological Chemistry 1997 272 24 15135 15144 2-s2.0-0030907589 10.1074/jbc.272.24.15135 (Pubitemid 27255528)
26. Tomida M., Heike T., Yokota T., Cytoplasmic domains of the leukemia inhibitory factor receptor required for STAT3 activation, differentiation, and growth arrest of myeloid leukemic cells. Blood 1999 93 6 1934 1941 2-s2.0-0033559707 (Pubitemid 29128495)
27. Hennessy B. T., Smith D. L., Ram P. T., Lu Y., Mills G. B., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews Drug Discovery 2005 4 12 988 1004 2-s2.0-32044466838 10.1038/nrd1902
28. Chien C.-M., Lin K.-L., Su J.-C., Chuang P.-W., Tseng C.-H., Chen Y.-L., Chang L.-S., Lin S.-R., Naphtho[1,2-b]furan-4,5-dione induces apoptosis of oral squamous cell carcinoma: involvement of EGF receptor/PI3K/Akt signaling pathway. The European Journal of Pharmacology 2010 636 1-3 52 58 2-s2.0-77952668738 10.1016/j.ejphar.2010.03.030
29. Suematsu S., Matsuda T., Aozasa K., Akira S., Nakano N., Ohno S., Miyazaki J., Yamamura K., Hirano T., Kishimoto T., IgG1 plasmacytosis in interleukin 6 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1989 86 19 7547 7551 2-s2.0-0345317621 (Pubitemid 19254493)
30. + T cells. The Journal of Experimental Medicine 1997 185 3 461 469 2-s2.0-0031058726 10.1084/jem.185.3.461 (Pubitemid 27078364)
31. Korn T., Bettelli E., Oukka M., Kuchroo V. K., IL-17 and Th17 cells. Annual Review of Immunology 2009 27 485 517 2-s2.0-61949463911 10.1146/annurev.immunol.021908.132710
32. Kimura A., Kishimoto T., IL-6: regulator of Treg/Th17 balance. European Journal of Immunology 2010 40 7 1830 1835 2-s2.0-77954096689 10.1002/eji.201040391
33. Nurieva R., Yang X. O., Martinez G., Zhang Y., Panopoulos A. D., Ma L., Schluns K., Tian Q., Watowich S. S., Jetten A. M., Dong C., Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007 448 7152 480 483 2-s2.0-34547204946 10.1038/nature05969 (Pubitemid 47123514)
34. + T cells. The Journal of Experimental Medicine 2008 205 6 1369 1379 2-s2.0-45149123617 10.1084/jem.20072057 (Pubitemid 351831493)
35. + T cells. The Journal of Experimental Medicine 2009 206 1 69 78 2-s2.0-60549105041 10.1084/jem.20081571
36. Suzuki M., Hashizume M., Yoshida H., Mihara M., Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatology International 2010 30 3 309 315 2-s2.0-73649103466 10.1007/s00296-009-0953-0
37. Kotake S., Sato K., Kim K. J., Takahashi N., Udagawa N., Nakamura I., Yamaguchi A., Kishimoto T., Suda T., Kashiwazaki S., Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. Journal of Bone and Mineral Research 1996 11 1 88 95 2-s2.0-13344250490 (Pubitemid 26026748)
38. Palmqvist P., Persson E., Conaway H. H., Lerner U. H., IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF- B ligand, osteoprotegerin, and receptor activator of NF- B in mouse calvariae. The Journal of Immunology 2002 169 6 3353 3362 2-s2.0-0037105542 (Pubitemid 35013185)
39. Suzuki M., Hashizume M., Yoshida H., Shiina M., Mihara M., IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. Cytokine 2010 51 2 178 183 2-s2.0-77954085343 10.1016/j.cyto.2010.03.017
40. Nakahara H., Song J., Sugimoto M., Hagihara K., Kishimoto T., Yoshizaki K., Nishimoto N., Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis & Rheumatism 2003 48 6 1521 1529 2-s2.0-0038798085 10.1002/art.11143 (Pubitemid 36682359)
41. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B. K., Ganz T., IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. The Journal of Clinical Investigation 2004 113 9 1271 1276 2-s2.0-2342510407 10.1172/JCI200420945 (Pubitemid 39069926)
42. Ishibashi T., Kimura H., Shikama Y., Uchida T., Kariyone S., Hirano T., Kishimoto T., Takatsuki F., Akiyama Y., Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989 74 4 1241 1244 2-s2.0-0024446495 (Pubitemid 19227430)
43. Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., Sato K., Shimizu M., Maini R., Feldmann M., Kishimoto T., Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. European Journal of Immunology 1988 18 11 1797 1801 2-s2.0-0024269961 (Pubitemid 19011590)
44. Holt I., Cooper R. G., Hopkins S. J., Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. European Journal of Clinical Investigation 1991 21 5 479 484 2-s2.0-0026047994
45. Dasgupta B., Corkill M., Kirkham B., Gibson T., Panayi G., Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. The Journal of Rheumatology 1992 19 1 22 25 2-s2.0-0026537579
46. Madhok R., Crilly A., Watson J., Capell H. A., Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Annals of the Rheumatic Diseases 1993 52 3 232 234 2-s2.0-0027518860 (Pubitemid 23094315)
47. Straub R. H., Müller-Ladner U., Lichtinger T., Schölmerich J., Menninger H., Lang B., Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. British Journal of Rheumatology 1997 36 12 1298 1303 2-s2.0-0344193128
48. Nishimoto N., Amano K., Hirabayashi Y., Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Modern Rheumatology 2014 24 1 17 25 10.1007/s10165-013-0894-z
49. Alonzi T., Fattori E., Lazzaro D., Costa P., Probert L., Kollias G., De Benedetti F., Poli V., Ciliberto G., Interleukin 6 is required for the development of collagen-induced arthritis. The Journal of Experimental Medicine 1998 187 4 461 468 2-s2.0-0032536542 10.1084/jem.187.4.461 (Pubitemid 28093348)
50. Sasai M., Saeki Y., Ohshima S., Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis & Rheumatism 1999 42 8 1635 1643 (Pubitemid 30263631)
51. Takagi N., Mihara M., Moriya Y., Blockade of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis & Rheumatism 1998 41 12 2117 2121 (Pubitemid 29009369)
52. Fujimoto M., Serada S., Mihara M., Uchiyama Y., Yoshida H., Koike N., Ohsugi Y., Nishikawa T., Ripley B., Kimura A., Kishimoto T., Naka T., Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis & Rheumatism 2008 58 12 3710 3719 2-s2.0-57349083145 10.1002/art.24126
53. Ohshima S., Saeki Y., Mima T., Sasai M., Nishioka K., Nomura S., Kopf M., Katada Y., Tanaka T., Suemura M., Kishimoto T., Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America 1998 95 14 8222 8226 2-s2.0-13144259627 10.1073/pnas.95.14.8222 (Pubitemid 28326094)
54. Wong P. K. K., Quinn J. M. W., Sims N. A., van Nieuwenhuijze A., Campbell I. K., Wicks I. P., Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis & Rheumatism 2006 54 1 158 168 2-s2.0-31044449633 10.1002/art.21537 (Pubitemid 43122198)
55. Sakaguchi N., Takahashi T., Hata H., Nomura T., Tagami T., Yamazaki S., Sakihama T., Matsutani T., Negishi I., Nakatsuru S., Sakaguchi S., Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003 426 6965 454 460 2-s2.0-0345414139 10.1038/nature02119 (Pubitemid 37490133)
56. Hata H., Sakaguchi N., Yoshitomi H., Iwakura Y., Sekikawa K., Azuma Y., Kanai C., Moriizumi E., Nomura T., Nakamura T., Sakaguchi S., Distinct contribution of IL-6, TNF- α IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. The Journal of Clinical Investigation 2004 114 4 582 588 2-s2.0-4344590199 10.1172/JCI200421795 (Pubitemid 39572108)
57. + Th cells that cause autoimmune arthritis. The Journal of Experimental Medicine 2007 204 1 41 47 2-s2.0-33846456970 10.1084/jem.20062259 (Pubitemid 46148754)
58. Sato K., Tsuchiya M., Saldanha J., Koishihara Y., Ohsugi Y., Kishimoto T., Bendig M. M., Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Research 1993 53 4 851 856 2-s2.0-0027502201 (Pubitemid 23077873)
59. Nishimoto N., Sasai M., Shima Y., Nakagawa M., Matsumoto T., Shirai T., Kishimoto T., Yoshizaki K., Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000 95 1 56 61 2-s2.0-0033959608 (Pubitemid 30017224)
60. Nishimoto N., Kanakura Y., Aozasa K., Johkoh T., Nakamura M., Nakano S., Nakano N., Ikeda Y., Sasaki T., Nishioka K., Hara M., Taguchi H., Kimura Y., Kato Y., Asaoku H., Kumagai S., Kodama F., Nakahara H., Hagihara K., Yoshizaki K., Kishimoto T., Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005 106 8 2627 2632 2-s2.0-27144488346 10.1182/blood-2004-12-4602 (Pubitemid 41510733)
61. Choy E. H. S., Isenberg D. A., Garrood T., Farrow S., Ioannou Y., Bird H., Cheung N., Williams B., Hazleman B., Price R., Yoshizaki K., Nishimoto N., Kishimoto T., Panayi G. S., Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis & Rheumatism 2002 46 12 3143 3150 2-s2.0-0036899812 10.1002/art.10623 (Pubitemid 35453522)
62. Nishimoto N., Yoshizaki K., Maeda K., Kuritani T., Deguchi H., Sato B., Imai N., Suemura M., Kakehi T., Takagi N., Kishimoto T., Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. The Journal of Rheumatology 2003 30 7 1426 1435 2-s2.0-0038166958 (Pubitemid 36835435)
63. Maini R. N., Taylor P. C., Szechinski J., Pavelka K., Bröll J., Balint G., Emery P., Raemen F., Petersen J., Smolen J., Thomson D., Kishimoto T., Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis & Rheumatism 2006 54 9 2817 2829 2-s2.0-33749363027 10.1002/art.22033 (Pubitemid 44497760)
64. Smolen J. S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., Woodworth T., Alten R., Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. The Lancet 2008 371 9617 987 997 2-s2.0-40749114497 10.1016/S0140-6736(08)60453-5 (Pubitemid 351392039)
65. Genovese M. C., McKay J. D., Nasonov E. L., Mysler E. F., Da Silva N. A., Alecock E., Woodworth T., Gomez-Reino J. J., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis & Rheumatism 2008 58 10 2968 2980 2-s2.0-54949150604 10.1002/art.23940
66. Emery P., Keystone E., Tony H. P., Cantagrel A., Van Vollenhoven R., Sanchez A., Alecock E., Lee J., Kremer J., IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Annals of the Rheumatic Diseases 2008 67 11 1516 1523 2-s2.0-52149099504 10.1136/ard.2008.092932
67. Kremer J. M., Blanco R., Brzosko M., Burgos-Vargas R., Halland A.-M., Vernon E., Ambs P., Fleischmann R., Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis & Rheumatism 2011 63 3 609 621 2-s2.0-79953680176 10.1002/art.30158
68. Jones G., Sebba A., Gu J., Lowenstein M. B., Calvo A., Gomez-Reino J. J., Siri D. A., Tomšič M., Alecock E., Woodworth T., Genovese M. C., Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases 2010 69 1 88 96 2-s2.0-73449118587 10.1136/ard.2008.105197
69. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Murata N., Van Heijde D. D., Kishimoto T., Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Annals of the Rheumatic Diseases 2007 66 9 1162 1167 2-s2.0-34447300492 10.1136/ard.2006.068064 (Pubitemid 47309731)
70. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J., Kishimoto T., Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Modern Rheumatology 2009 19 1 12 19 2-s2.0-60149105639 10.1007/s10165-008-0125-1
71. Yamanaka H., Tanaka Y., Inoue E., Hoshi D., Momohara S., Hanami K., Yunoue N., Saito K., Amano K., Kameda H., Takeuchi T., Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Modern Rheumatology 2011 21 2 122 133 2-s2.0-79960128977 10.1007/s10165-010-0366-7
72. Takeuchi T., Tanaka Y., Amano K., Hoshi D., Nawata M., Nagasawa H., Sato E., Saito K., Kaneko Y., Fukuyo S., Kurasawa T., Hanami K., Kameda H., Yamanaka H., Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology 2011 50 10 1908 1915 2-s2.0-80053141949 10.1093/rheumatology/ker221
73. Dougados M., Kissel K., Sheeran T., Tak P. P., Conaghan P. G., Mola E. M., Schett G., Amital H., Navarro-Sarabia F., Hou A., Bernasconi C., Huizinga T. W. J., Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Annals of the Rheumatic Diseases 2012 72 1 43 50 2-s2.0-84860521298 10.1136/annrheumdis-2011-201282
74. Gabay C., Emery P., van Vollenhoven R., Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. The Lancet 2013 381 9877 1541 1550
75. Emery P., Sebba A., Huizinga T. W., Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Annals of the Rheumatic Diseases 2013 10.1136/annrheumdis-2013-203485
76. Singh J. A., Saba B., Lopez-Olivo M. A., Tocilizumab for rheumatoid arthritis: a cochrane systematic review. The Journal of Rheumatology 2011 38 1 10 20 2-s2.0-78650907772 10.3899/jrheum.100717
77. Ogata A., Tanimura K., Sugimoto T., A phase 3 study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis (MUSASHI). Arthritis Care & Research 2013 10.1002/acr.22110
78. Burmester G. R., Rubbert-Roth A., Cantagrel A., A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Annals of the Rheumatic Diseases 2013 73 1 69 74 10.1136/annrheumdis-2013-203523
79. Schiff M. H., Kremer J. M., Jahreis A., Vernon E., Isaacs J. D., van Vollenhoven R. F., Integrated safety in tocilizumab clinical trials. Arthritis Research and Therapy 2011 13 5, article R141 2-s2.0-80052137402 10.1186/ar3455
80. Koike T., Harigai M., Inokuma S., Ishiguro N., Ryu J., Takeuchi T., Takei S., Tanaka Y., Ito K., Yamanaka H., Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Annals of the Rheumatic Diseases 2011 70 12 2148 2151 2-s2.0-82755160877 10.1136/ard.2011.151092
81. Singh J. A., Wells G. A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J. K., Filippini G., Skoetz N., Francis D., Lopes L. C., Guyatt G. H., Schmitt J., La Mantia L., Weberschock T., Roos J. F., Siebert H., Hershan S., Lunn M. P., Tugwell P., Buchbinder R., Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011 2 CD008794 2-s2.0-79953018875
82. Genovesse M. C., Rubbert-Roth A., Smolen J. S., Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. The Journal of Rheumatology 2013 40 6 768 780
83. Gout T., Östör A. J. K., Nisar M. K., Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clinical Rheumatology 2011 30 11 1471 1474 2-s2.0-80755182205 10.1007/s10067-011-1827-x
84. Hashizume M., Yoshida H., Koike N., Suzuki M., Mihara M., Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Annals of the Rheumatic Diseases 2010 69 4 741 746 2-s2.0-77950335656 10.1136/ard.2008.104844
85. Huizinga T. W., Kivitz A. J., Rell-Bakalarska M., Sarilumab for the treatment of moderate to severe rheumatoid arthritis: results of a phase 2, randomized, double-blind, placebo-controlled, international study. Annals of the Rheumatic Diseases 2012 71 supplement 3 60
86. Hsu B., Sheng S., Smolen J. S., Weinblatt M. E., Results from a 2-part, proof of concept, dose ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy. Annals of the Rheumatic Diseases 2012 71 supplement 3 188
87. Kanbe K., Nakamura A., Inoue Y., Hobo K., Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. Rheumatology International 2012 32 9 2669 2674 2-s2.0-79960556769 10.1007/s00296-011-2021-9
88. Terpos E., Fragiadaki K., Konsta M., Bratengeier C., Papatheodorou A., Sfikakis P. P., Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clinical and Experimental Rheumatology 2011 29 6 921 925 2-s2.0-84857534016
89. Bay-Jensen A. C., Platt A., Byrjalsen I., Vergnoud P., Christiansen C., Karsdal M. A., Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Seminars in Arthritis and Rheumatism 2013 10.1016/j.semarthrit.2013.07.008
90. Tanaka T., Can IL-6 blockade rectify imbalance between Tregs and Th17 cells? Immunotherapy 2013 5 7 695 697
91. Samson M., Audia S., Janikashvili N., Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis & Rheumatism 2012 64 8 2499 2503
92. Pesce B., Soto L., Sabugo F., Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clinical & Experimental Immunology 2013 171 3 237 242
93. Carbone G., Wilson A., Diehl S. A., Bunn J., Cooper S. M., Ricon M., Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. International Journal of Biological Sciences 2013 9 3 279 288
94. Liu R., Wu Q., Su D., A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthritis Research & Therapy 2012 23 14, article R255 10.1186/ar4100
95. Fishman D., Faulds G., Jeffey R., Mohamed-Ali V., Yudkin J. S., Humphries S., Woo P., The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic- onset juvenile chronic arthritis. The Journal of Clinical Investigation 1998 102 7 1369 1376 2-s2.0-0032189103 (Pubitemid 28467565)
96. Lee Y. H., Bae S.-C., Choi S. J., Ji J. D., Song G. G., Associations between TNFAIP3 gene polymorphisms and rheumatoid arthritis: a meta-analysis. Inflammation Research 2012 61 7 665 671 2-s2.0-84857714041 10.1007/s00011-012- 0455-5
97. Tanaka T., Narazaki M., Masuda K., Kishimoto T., Interleukin-6, pathogenesis and treatment of autoimmune inflammatory diseases. Inflammation and Regeneration 2013 33 1 54 65
98. Matsushita K., Takeuchi O., Standley D. M., Kumagai Y., Kawagoe T., Miyake T., Satoh T., Kato H., Tsujimura T., Nakamura H., Akira S., Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 2009 458 7242 1185 1190 2-s2.0-67349167059 10.1038/nature07924
99. Iwasaki H., Takeuchi O., Teraguchi S., Matsushita K., Uehata T., Kuniyoshi K., Satoh T., Saitoh T., Matsushita M., Standley D. M., Akira S., The I B kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nature Immunology 2011 12 12 1167 1175 2-s2.0-81255154489 10.1038/ni.2137
100. Masuda K., Ripley B., Nishimura R., Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proceedings of the National Academy of Sciences of the United States of America 2013 110 23 9409 9414